课题基金 / 基金详情

Endothelial hiPSC-Cardiomyocyte Interactions Relevant to Model Disease and Aging

Endothelial hiPSC-Cardiomyocyte Interactions Relevant to Model Disease and Aging
与模型疾病和衰老相关的内皮 hiPSC-心肌细胞相互作用
批准号:
8851826
负责人:
MARK MERCOLA
金额:
$19.38万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-15 至 2015-06-30

项目摘要

项目成果

MARK MERCOLA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In principle, differentiated cardiomyocytes derived from hESCs and hiPSCs are ideal model systems in which to study the physiological effects of disease and aging. However, hESC/hiPSC-derived cardiomyocytes characteristically exhibit electrical and mechanical properties of early fetal, rather than adult, cells. Although a few growt factor-like molecules are reported to have a maturational effect, little is known about the precise physiological effects or how the molecules can be used to improve the utility of hiPSC/hESC-derived cardiomyocytes to model aging and disease. The goal of this R21 proposal is to identify and characterize such molecules, based on preliminary data that endothelial cells normally produce maturation-inducing factors. Data are presented showing the development of instrumentation and software for high-throughput assessment of electrophysiological maturation. Using this technology, we provide preliminary evidence that endothelial cells (ECs) promote electrical and ion channel profile maturation of hiPSC/ESC-derived cardiomyocytes through the production of factors that accumulate in conditioned media. The specific aims of this proposal are to: 1) define EC-induced maturation by functional expression of ion channels and pumps, drug sensitivity profiling, action potential and calcium handling metrics, 2) determine if ECs also promote maturation of contractile apparatus structure and function, and 3) use the electrical and mechanical metrics from Aims 1 and 2 as quantitative metrics to identify and characterize the effects of EC-derived maturation factor(s). The identification of signals that promote cardiomyocyte maturation should lead to improved methods for deriving functional cardiomyocytes that will be enabling for studies of aging and disease. Beyond the high- risk/high-yield scope of the R21 project, we have established collaborations to evaluate whether the maturational factors indeed enhance the utility of hiPSC-cardiomyocytes as models for drug risk assessment and disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
  • 批准号:
    10716393
  • 项目类别:
  • 资助金额:
    $57.24万
  • 财政年份:
    2023
  • 负责人:
    MARK MERCOLA
  • 依托单位:
High throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug development
  • 批准号:
    10745000
  • 项目类别:
  • 资助金额:
    $46.32万
  • 财政年份:
    2023
  • 负责人:
    MARK MERCOLA
  • 依托单位:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
  • 批准号:
    10355529
  • 项目类别:
  • 资助金额:
    $58.56万
  • 财政年份:
    2021
  • 负责人:
    MARK MERCOLA
  • 依托单位:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
  • 批准号:
    10576285
  • 项目类别:
  • 资助金额:
    $58.33万
  • 财政年份:
    2021
  • 负责人:
    MARK MERCOLA
  • 依托单位:
海外基金